J&J’s COVID Vaccine Contract With US Bucks Trend Of Increasingly Lucrative Deals
Estimated $14 price per dose for Janssen’s investigational vaccine is first drop in value since Operation Warp Speed started signing contracts. The $1bn purchase order for 100 million doses and earlier $456m for development work is considerably less lucrative than the $2.1bn deal with GSK/Sanofi announced last week, especially since Janssen’s product may end up being a one-dose regimen.
You may also be interested in...
Effectiveness can be evaluated more quickly because researchers won’t have to wait for the second dose, company executive notes during briefing on the launch of the Phase III study.
The possibility, which seems driven by the culture of the times, may be legally possible, but experts raised many practical concerns.
Cigna's Steve Miller suggests pharma is taking a responsible approach to pricing during the pandemic in a policy discussion convened by the Institute for Clinical and Economic Review on pricing models for COVID-19 drugs and vaccines.